7,653.75

+39.75

+0.52%

52,217.00

+299.00

+0.58%

28,776.00

+242.00

+0.85%

Russell 2000 Futures

2,843.10

+21.80

+0.77%

4.9290

-0.0600

-1.20%

18.97

-0.45

-2.32%

3,913.20

+14.30

+0.37%

77,742.94

-87.13

-0.11%

Crude Oil Dec 26

99.34

-4.78

-4.59%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGS - Nasdaq Real Time Price USD

InflaRx N.V. (IFRX)

1.6600 -0.0550 (-3.21%)

At close: October 30 at 4:00:01 PM EDT

Loading Chart for IFRX

Chart Range Bar

Interval:

In partnership with ChartIQ

InflaRx Announces November Investor Events

InflaRx Announces November Investor Events

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

InflaRx Announces Participation in September Investor Conferences

InflaRx Announces Participation in September Investor Conferences

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx N.V. (IFRX) Regains Compliance With Nasdaq

InflaRx N.V. (IFRX) Regains Compliance With Nasdaq

Mobilize your Website

View Site in Mobile | Classic

Share by: